Updated · Investors | Eli Lilly and Company · Jun 13
Lilly Reports 70% Response Rates for AJ1-11095 in 23 Myelofibrosis Patients
Updated
Updated · Investors | Eli Lilly and Company · Jun 13
Lilly Reports 70% Response Rates for AJ1-11095 in 23 Myelofibrosis Patients
3 articles · Updated · Investors | Eli Lilly and Company · Jun 13
Summary
AJ1-11095 delivered a 70% SVR35 best-response rate and a 70% TSS50 rate at week 12 in Lilly’s initial Phase 1 data for previously treated myelofibrosis patients.
The dose-escalation cohort covered 23 patients across five once-daily dose levels; all had previously received a type I JAK2 inhibitor and had a median of two prior therapies.
Variant allele frequency fell in 21 of 23 patients, and among 17 patients treated for 24 weeks, 59% had reductions of at least 20% while 35% reached at least 50%.
No dose-limiting toxicities were observed, the safety profile was described as manageable, and 78% of dose-escalation patients remain on study despite adverse events including anemia and decreased platelet count.
Lilly plans to present the data at the 2026 EHA meeting as it expands AJ1-11095 into second-line myelofibrosis and studies in high-risk polycythemia vera and JAK2-inhibitor-naive patients.
With its novel mechanism, will Lilly's new inhibitor make current blockbuster myelofibrosis drugs obsolete?
This drug reduces the cancer's driver mutation. Does this signal a real chance at remission or just a different set of treatment trade-offs?
AJ1-11095’s Phase 1 Success: High Molecular Response Rates Offer New Hope for Myelofibrosis Patients After JAK Inhibitor Failure
Overview
Ajax Therapeutics presented promising Phase 1 results for AJ1-11095, a new type II JAK2 inhibitor, at the EHA 2026 Congress. This drug showed strong efficacy in myelofibrosis patients who had already tried and failed type I JAK inhibitors, a group with few treatment options. The trial revealed high spleen and symptom responses, offering real clinical benefits for these difficult cases. These findings bring new hope to patients with critical unmet needs, marking a significant step forward in myelofibrosis treatment and highlighting AJ1-11095’s potential as a breakthrough therapy.